Timothy Harrison

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

Phillip Monk, Richard Marsden, Victoria Tear et al. · The Lancet Respiratory Medicine · 2020 · 448 citations · Full text

Sars-cov-2 Infection, Covid-19 Pandemic, Immunology +4

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

William W. Busse, Eugene R. Bleecker, J Mark FitzGerald et al. · The Lancet Respiratory Medicine · 2018 · 298 citations

Asthma, Rheumatology, Extension Trial +10

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

Tim Harrison, Pascal Chanez, Francesco Menzella et al. · The Lancet Respiratory Medicine · 2020 · 168 citations · Full text

Asthma, Severe Eosinophilic Asthma, Allergy +10

Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study

Andrew Menzies‐Gow, Mark Gurnell, Liam G. Heaney et al. · The Lancet Respiratory Medicine · 2021 · 165 citations

Asthma, Allergy, Personalised Reduction Algorithm +9

Inhaled Corticosteroids and the Risk of Pneumonia in People With Asthma

Tricia M. McKeever, Timothy Harrison, Richard Hubbard et al. · CHEST Journal · 2013 · 150 citations · Full text

Asthma, Allergy, Inflammatory Lung Disease +6